2.635  0.075 (2.93%)		05-11 12:25
Open: 2.59 High: 2.73 Volume: 255,970		Pre. Close: 2.56 Low: 2.59 Market Cap: 160(M)

Short term
Mid term
Targets	6-month :	3.49	1-year :	4.07
Resists	First :	2.99	Second :	3.49
Pivot price	2.54
Supports	First :	2.58	Second :	2.32
MAs	MA(5) :	2.55	MA(20) :	2.59
	MA(100) :	2.51	MA(250) :	1.92
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	39.5	D(3) :	33
RSI	RSI(14): 54
52-week	High :	3.59	Low :	0.97

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ABOS ] has closed below upper band by 24.4%. Bollinger Bands are 34.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.57 - 2.58	2.58 - 2.59
Low:	2.38 - 2.4	2.4 - 2.41
Close:	2.54 - 2.56	2.56 - 2.58

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Mon, 11 May 2026
Is Acumen Pharmaceuticals (ABOS) stock outpacing its medical peers this year? - MSN

Sun, 10 May 2026
Acumen Pharmaceuticals (ABOS) loses 33.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN

Thu, 07 May 2026
Acumen executives take Bank of America health care stage May 14 - Stock Titan

Wed, 06 May 2026
Acumen Pharmaceuticals (ABOS.US) will release its earnings report before the market opens on May 12. - Moomoo

Tue, 05 May 2026
Acumen sets May 12 earnings update, webcast starts at 8 a.m. ET - Stock Titan

Thu, 23 Apr 2026
Acumen (NASDAQ: ABOS) seeks approval for major equity plan expansion - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	72 (M)
Shares Float	41 (M)
Held by Insiders	6.6 (%)
Held by Institutions	58.7 (%)
Shares Short	1,550 (K)
Shares Short P.Month	1,030 (K)

EPS	-2
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.15
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-42.8 %
Return on Equity (ttm)	-96.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-1.46
Sales Per Share	0
EBITDA (p.s.)	-1.72
Qtrly Earnings Growth	0 %
Operating Cash Flow	-116 (M)
Levered Free Cash Flow	-75 (M)

PE Ratio	-1.34
PEG Ratio	0
Price to Book value	2.3
Price to Sales	0
Price to Cash Flow	-1.68

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.